Drug Profile
DNL 151
Alternative Names: BIIB-122; DNL-151Latest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Genentech
- Developer Biogen; Denali Therapeutics Inc
- Class Antiparkinsonians; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Parkinson's disease
Most Recent Events
- 23 Feb 2024 Biogen plans a phase I drug-drug interaction trial (In volunteers) (PO) in February 2024 (NCT06264440)
- 12 Feb 2024 Biogen initiates a phase I drug-drug interaction trial (In volunteers) (PO) (NCT06264440)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Parkinson's-disease in Belgium (PO, Tablet)